Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
I.YazdiZ
The landmark cardiovascular outcomes trialsincluding SUSTAIN-6 for semaglutide and LEADER for liraglutidespecifically evaluated cardiovascular safety endpoints and did not report increased rates of venous thromboembolism compared to placebo, though it's important to note that VTE was not a primary endpoint in these studies
A 2021 analysis of semaglutide clinical trials found an increased risk of DVTs in patients who took the drug
After four weeks, your payment will increase to $24.95 plus GST every four weeks
US$ 25.81
:max_bytes(150000):strip_icc()/Health-GettyImages-2153927815-0bf99cd73e2c46908d7fc0973739f6d0.jpg)
.jpg)
US$ 27.87
US$ 23.36
